Back

Abbisko reports 2.4 cm/year height-velocity gain in ACH trial

Verifying
  • Abbisko Therapeutics reported preliminary Phase II lavengratinib results in children with achondroplasia.
  • Seven children receiving 0.064 mg/kg daily achieved a 2.4 cm/year mean height-velocity increase.
  • The ABSK061-202 study covers children aged 3 to 12 over 78 weeks.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.